Emma Allen-Vercoe | |
---|---|
Alma mater | Veterinary Laboratories Agency Health Protection Agency |
Scientific career | |
Institutions | University of Calgary University of Guelph |
Thesis | The role of fimbriae and flagella in the pathogenesis of Salmonella enteritidis phage-type 4 infections. (1999) |
Emma Allen-Vercoe is a British-Canadian Molecular biologist who is a Professor and Canada Research Chair at the University of Guelph. Her research considers the gut microbiome and microbial therapeutics to treat Escherichia coli.
Allen-Vercoe was an undergraduate student at the Veterinary Laboratories Agency. She moved to the Health Protection Agency for her graduate studies, where she worked under the supervision of Martin Woodward. Here she studied Salmonella enterica and the processes by which enteric pathogens cause disease. She was a postdoctoral researcher at the Health Protection Agency. During her doctorate, she studied Mycobacterium tuberculosis and Campylobacter jejuni . [1]
In 2001, Allen-Vercoe moved to Canada, where she joined the University of Calgary. Allen-Vercoe worked on Escherichia coli . In 2004, she was awarded a Canadian Association of Gastroenterology Fellow-to-Faculty Transition Award. [1] [2] She moved to the University of Guelph in 2007. [1] Her research considers the gut microbiome. [3] [4] She worked with the biotechnology company Infors to create a bioreactor that can maintain biological samples in specific anaerobic atmospheres whilst her research team studying the constituents microbes. [4]
Allen-Vercoe isolates bacteria from human stool samples, places them in the so-called robo-gut and monitors their behaviour in precise conditions. [5] [6] For example, the robo-gut (or mechanical colon) can recreate environments that allow for particular genes and bacteria to thrive, which allows Allen-Vercoe to study the microbiobes associated with certain medical conditions. [4] [7] Allen-Vercoe has identified the general bacteria that exist in all microbiomes, as well as monitoring the microbiome's metabolomics. [8] She has worked on microbial therapeutics to treat various diseases, including Clostridioides difficile infection and cancer. [9] [10]
Allen-Vercoe launched the NuBiyota in 2013, a biotechnology company that looks to grow microbes in a controlled environment. [11] She was awarded a Tier 1 Canada Research Chair in 2019, which allowed her to study the influence of the gut microbiome on health and disease. [12]
Bonnie Lynn Bassler is an American molecular biologist; the Squibb Professor in Molecular Biology and chair of the Department of Molecular Biology at Princeton University; and a Howard Hughes Medical Institute Investigator. She has researched cell-to-cell chemical communication in bacteria and discovered key insights into the mechanism by which bacteria communicate, known as quorum sensing. She has contributed to the idea that disruption of chemical signaling can be used as an antimicrobial therapy.
The human microbiome is the aggregate of all microbiota that reside on or within human tissues and biofluids along with the corresponding anatomical sites in which they reside, including the skin, mammary glands, seminal fluid, uterus, ovarian follicles, lung, saliva, oral mucosa, conjunctiva, biliary tract, and gastrointestinal tract. Types of human microbiota include bacteria, archaea, fungi, protists, and viruses. Though micro-animals can also live on the human body, they are typically excluded from this definition. In the context of genomics, the term human microbiome is sometimes used to refer to the collective genomes of resident microorganisms; however, the term human metagenome has the same meaning.
Gut microbiota, gut microbiome, or gut flora, are the microorganisms, including bacteria, archaea, fungi, and viruses, that live in the digestive tracts of animals. The gastrointestinal metagenome is the aggregate of all the genomes of the gut microbiota. The gut is the main location of the human microbiome. The gut microbiota has broad impacts, including effects on colonization, resistance to pathogens, maintaining the intestinal epithelium, metabolizing dietary and pharmaceutical compounds, controlling immune function, and even behavior through the gut–brain axis.
Martin J. Blaser is the director of the Center for Advanced Biotechnology and Medicine at Rutgers (NJ) Biomedical and Health Sciences and the Henry Rutgers Chair of the Human Microbiome and Professor of Medicine and Pathology and Laboratory Medicine at the Rutgers Robert Wood Johnson Medical School in New Jersey.
Dysbiosis is characterized by a disruption to the microbiome resulting in an imbalance in the microbiota, changes in their functional composition and metabolic activities, or a shift in their local distribution. For example, a part of the human microbiota such as the skin flora, gut flora, or vaginal flora, can become deranged, with normally dominating species underrepresented and normally outcompeted or contained species increasing to fill the void. Dysbiosis is most commonly reported as a condition in the gastrointestinal tract.
Microbiota are the range of microorganisms that may be commensal, mutualistic, or pathogenic found in and on all multicellular organisms, including plants. Microbiota include bacteria, archaea, protists, fungi, and viruses, and have been found to be crucial for immunologic, hormonal, and metabolic homeostasis of their host.
For the American folk-rock singer-songwriter, see Nancy Moran.
John David Spence is a Canadian medical doctor, medical researcher and Professor Emeritus at the University of Western Ontario. He is affiliated with the University of Western Ontario and the Robarts Research Institute, one of Canada's leading medical research organizations. Before his retirement from clinical practice in July 2022, he was also affiliated with the London Health Sciences Centre's University Hospital. He is a recognized expert in stroke prevention and stroke prevention research, with more than 600 peer-reviewed publications since 1970. He delivered more than 600 lectures on stroke prevention in 42 countries. In 2015, he received the Research Excellence Award from the Canadian Society for Atherosclerosis, Thrombosis and Vascular Biology. In 2019, he was appointed a Member of the Order of Canada, and in 2020 he received the William Feinberg Award from the American Heart Association for excellence in clinical stroke research.
Curtis Huttenhower is a Professor of Computational Biology and Bioinformatics in the Department of Biostatistics, School of Public Health, Harvard University.
Yasmine Belkaid is an Algerian immunologist and senior investigator at the National Institute of Allergy and Infectious Diseases (NIAID) and adjunct professor at the University of Pennsylvania. She is best known for her work studying host-microbe interactions in tissues and immune regulation to microbes. Belkaid currently serves as the director of the NIAID Microbiome program. On 29 March 2023, she was appointed as President of the Pasteur Institute for a six-year term, starting from January 2024.
Katherine Snowden Pollard is the Director of the Gladstone Institute of Data Science and Biotechnology and a professor at the University of California, San Francisco (UCSF). She is a Chan Zuckerberg Biohub Investigator. She was awarded Fellowship of the International Society for Computational Biology in 2020 and the American Institute for Medical and Biological Engineering in 2021 for outstanding contributions to computational biology and bioinformatics.
Maria Gloria Dominguez-Bello is a Venezuelan-American microbial ecologist that has worked on adaptations of gut fermentation organs in animals, gastric colonization by bacteria, assembly of the microbiota in early life, effect of practices that reduce microbiota transmission and colonization in humans, and effect of urbanization. She is the Henry Rutgers Professor of Microbiome and Health at Rutgers University, New Brunswick. Her lab at collaborates in multidisciplinary science, integrating microbiology, immunology, pediatrics, nutrition, anthropology, environmental engineering and architecture/urban studies, and microbial ecology.
Colibactin is a genotoxic metabolite produced by Escherichia coli and other Enterobacteriaceae believed to cause mutations leading to colorectal cancer and the progression of colorectal cancer. Colibactin is a polyketide peptide that can form interstrand crosslinks in DNA. Colibactin is only produced by bacterial strains containing a polyketide synthase genomic island (pks) or clb biosynthetic gene cluster. About 20% of humans are colonized with E. coli that harbor the pks island.
Megan Frederickson is a Canadian evolutionary biologist who is a professor of Ecology and Evolutionary Biology at the University of Toronto. Her research considers the evolution of cooperation and the ecological genetics of mutualism.
Elaine Yih-Nien Hsiao is an American biologist who is Professor in Biological Sciences at University of California, Los Angeles. Her research considers the microbes that impact human health. She was a 2022 Laureate for the Blavatnik Awards for Young Scientists.
Bile salt hydrolases (BSH) are microbial enzymes that deconjugate primary bile acids. They catalyze the first step of bile acid metabolism and maintain the bile acid pool for further modification by the microbiota. BSH enzymes play a role in a range of host and microbe functions including host physiology, immunity, and protection from pathogens.
Sidonia Făgărășan is a Romanian biological scientist who is a professor at the Riken Institute in Japan. Her research considers the molecular mechanisms that underpin processes in gut microbioata and the mucosal barrier. In 2020, she was awarded the Kobayashi Foundation Award.
Janet Knutson Jansson is an American biological scientist who is the Chief Scientist at the Pacific Northwest National Laboratory. She investigates complex microbial communities, including those found in soil and the human gut. Jansson is part of the Phenotypic Response of the Soil Microbiome to Environmental Perturbations Science Focus Area, and is a Fellow of the American Society for Microbiology.
Debbie Lindsay Shawcross is a British physician and clinician who is a professor at King's College London. Her research looks to better understand the cellular and molecular mechanisms that underpin chronic liver disease, with a focus on the gut-liver-brain axis.